Austin-based biotech firm Cassava Sciences, Inc. is focused on developing innovative drugs to combat neurodegenerative diseases, with its lead product candidate being the promising small molecule drug, simufilam. The drug has emerged as a standout candidate with the completion of its Phase 2b clinical trial. Additionally, the company is also working on an investigational diagnostic product, SavaDx, which uses blood-based biomarkers to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc., and underwent a name change in March of last year. The pioneering company was established in 1998, and has since remained committed to its mission to advance the treatment of neurodegenerative diseases.